title: Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma.
abstract: Although external beam radiation is an essential component to the current standard treatment of primary brain tumors, its application is limited by toxicity at doses more than 80 Gy. Recent studies have suggested that brachytherapy with liposomally encapsulated radionuclides may be of benefit, and we have reported methods to markedly increase the specific activity of rhenium-186 ((186)Re)-liposomes. To better characterize the potential delivery, toxicity, and efficacy of the highly specific activity of (186)Re-liposomes, we evaluated their intracranial application by convection-enhanced delivery in an orthotopic U87 glioma rat model. After establishing an optimal volume of 25 µL, we observed focal activity confined to the site of injection over a 96-hour period. Doses of up to 1850 Gy were administered without overt clinical or microscopic evidence of toxicity. Animals treated with (186)Re-liposomes had a median survival of 126 days (95% confidence interval [CI], 78.4-173 days), compared with 49 days (95% CI, 44-53 days) for controls. Log-rank analysis between these 2 groups was highly significant (P = .0013) and was even higher when 100 Gy was used as a cutoff (P < .0001). Noninvasive luciferase imaging as a surrogate for tumor volume showed a statistically significant separation in bioluminescence by 11 days after 100 Gy or less treatment between the experimental group and the control animals (χ(2)[1, N= 19] = 4.8; P = .029). MRI also supported this difference in tumor size. Duplication of tumor volume differences and survival benefit was possible in a more invasive U251 orthotopic model, with clear separation in bioluminescence at 6 days after treatment (χ(2)[1, N= 9] = 4.7; P = .029); median survival in treated animals was not reached at 120 days because lack of mortality, and log-rank analysis of survival was highly significant (P = .0057). Analysis of tumors by histology revealed minimal areas of necrosis and gliosis. These results support the potential efficacy of the highly specific activity of brachytherapy by (186)Re-liposomes convection-enhanced delivery in glioma.
authors.affiliation: Department of Radiology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
authors.forename: William T
authors.initials: WT
authors.lastname: Phillips
authors.forename: Beth
authors.initials: B
authors.lastname: Goins
authors.forename: Ande
authors.initials: A
authors.lastname: Bao
authors.forename: Daniel
authors.initials: D
authors.lastname: Vargas
authors.forename: Juan E
authors.initials: JE
authors.lastname: Guttierez
authors.forename: Abram
authors.initials: A
authors.lastname: Trevino
authors.forename: Jessica R
authors.initials: JR
authors.lastname: Miller
authors.forename: James
authors.initials: J
authors.lastname: Henry
authors.forename: Richard
authors.initials: R
authors.lastname: Zuniga
authors.forename: Giacomo
authors.initials: G
authors.lastname: Vecil
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Brenner
mesh_terms: D000818:Animals; D001918:Brachytherapy / Q000379:methods*; D001932:Brain Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D018481:Convection; D005909:Glioblastoma / Q000473:pathology / Q000532:radiotherapy*; D005910:Glioma / Q000473:pathology / Q000532:radiotherapy*; D008081:Liposomes; D053758:Nanoparticles / Q000627:therapeutic use; D011868:Radioisotopes / Q000627:therapeutic use*; D051381:Rats; D012211:Rhenium / Q000627:therapeutic use*; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays
chemical_list: D008081:Liposomes; D011868:Radioisotopes; D012211:Rhenium